Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lir Life SciencesBBCMF 15 Equity-to-Asset is 0.93 as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,416 Biotechnology companies, Lir Life Sciences ranks better than 90.11% on this metric.
The historical rank and industry rank for Lir Life Sciences's Equity-to-Asset or its related term are showing as below:
BBCMF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.45 Med: -0.14 Max: 0.97
Current: 0.93
During the past 2 years, the highest Equity to Asset Ratio of Lir Life Sciences was 0.97. The lowest was -2.45. And the median was -0.14.
BBCMF's Equity-to-Asset is ranked better than 90.11% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs BBCMF: 0.93
Lir Life Sciences (OTCPK:BBCMF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lir Life Sciences Equity-to-Asset Related Terms
Lir Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBCMF vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Lir Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lir Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a Equity-to-Asset of 0.93 as of Jan. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #140 out of 1416 companies in the Biotechnology industry, placing it in the top 9.9%.
Is Lir Life Sciences' Equity-to-Asset too high?
Lir Life Sciences' current Equity-to-Asset is 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. Lir Life Sciences' value of 0.93 is 36.8% above this industry median. Based on the distribution chart, Lir Life Sciences ranks #140 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #140 out of 1416 companies for Equity-to-Asset. This places Lir Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Lir Life Sciences' value of 0.93 is 36.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Equity-to-Asset of 0.93 is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Equity-to-Asset is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Equity-to-Asset of 0.93. The current Equity-to-Asset is 0.93 and 36.8% above the Biotechnology industry median of 0.68. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Equity-to-Asset is 0.93 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 
